中低收入国家的临床试验准入：以印度为例。
Clinical Trial Access in Low- and Middle-Income Countries: A Case Study on India.
机构信息
Division of Medical Oncology, Department of Medicine, Mayoclinic, Rochester, MN, USA.
Division of Hematology, Department of Medicine, MayoClinic, Rochester, MN, USA.
出版信息
Cancer Invest. 2021 Oct;39(9):685-689. doi: 10.1080/07357907.2021.1912078. Epub 2021 Sep 1.
The global burden of cancer is estimated to be more than 20 million cases by 2030, the majority occurring in low- and middle- income countries (LMICs). LMICs account for 64% of global cancer deaths and 80% of disability-adjusted-life-years lost. Despite this, only 5% of the global cancer resources are spent in LMICs causing a high mortality-to-income ratio. Despite the burgeoning number of clinical trials in the HICs, there are several reasons to conduct clinical trials in LMICs. In this commentary, we discuss the problem of access to clinical trials in LMICs using India as a case study.
据估计，到 2030 年，全球癌症负担将超过 2000 万例，其中大多数发生在低收入和中等收入国家（LMICs）。LMICs 占全球癌症死亡人数的 64%，占失能调整生命年的 80%。尽管如此，全球癌症资源的 5%仅用于 LMICs，导致高死亡率与收入比。尽管在高收入国家（HICs）进行的临床试验数量不断增加，但在 LMICs 进行临床试验有几个原因。在这篇评论中，我们使用印度作为案例研究来讨论 LMICs 获得临床试验的问题。
Zotero 插件